Acadia Plans Early FDA Filing Of Parkinson's Drug

SAN DIEGO ( TheStreet) -- Acadia Pharmaceuticals ( ACAD) is taking the express lane to U.S approval for its Parkinson's disease psychosis drug, lifting shares higher in early Thursday trading.

After meeting with the U.S. Food and Drug Administration, Acadia intends to file an approval application for pimavanserin based on data from a successful phase III study completed last year, plus other supportive data.

The company will no longer conduct a confirmatory phase III study that was planned to begin later this month.

The FDA approval filing for pimavanserin as a treatment for Parkinson's psychosis is expected near the end of 2014. FDA will subject the pimavanserin filing to a standard review, which suggests a review cycle of 12 months. If approved, pimavanserin could reach the U.S. market in late 2015.

Acadia shares are up 25% to $9.94 in pre-market trading.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Biotech M&A: Who's Next After Gilead-Kite?

'Longing' for Acadia Pharmaceuticals? Here's How to Play It

3 Housing Plays With Solid Earnings

7 Potential New Targets for Activist Investor That Made a Killing on Whole Foods

Jana Partners Liquidates Whole Foods Stake After Engineering Industry-Transforming Sale To Amazon